335 results on '"Choueiri T"'
Search Results
2. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
3. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
4. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
5. Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial
6. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer
7. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
8. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
9. Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101
10. The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective
11. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
12. Supplement to: Cabozantinib versus everolimus in advanced renal-cell carcinoma.
13. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act
14. Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab + Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR)
15. Nivolumab + Cabozantinib (N+C) vs Sunitinib (S) en première ligne (1L) de traitement chez des patients atteints d’un carcinome rénal avancé (ACCR) dans l’essai de phase III checkmate 9ER : analyse en sous-groupes basée sur l’absence ou présence de néphrectomie antérieure
16. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
17. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
18. Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design
19. Incidence and determinants of 1-month mortality after cancer-directed surgery
20. CheckMate-9ER-Studie: Nivolumab + Cabozantinib im Vergleich zu Sunitinib bei fortgeschrittenem Nierenzellkarzinom - aktualisierte Ergebnisse mit verlängerter Nachbeobachtung und bei sarkomatoider Histologie
21. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer
22. Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC) : Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms
23. CheckMate-9ER-Studie: Nivolumab + Cabozantinib im Vergleich zu Sunitinib bei fortgeschrittenem Nierenzellkarzinom - aktualisierte Ergebnisse mit verlängerter Nachbeobachtung und bei sarkomatoider Histologie
24. O12 - Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial
25. PD-L1 expression in nonclear-cell renal cell carcinoma
26. A phase I study of cabozantinib (XL184) in patients with renal cell cancer
27. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
28. METEOR Studie: Analyse des Gesamtüberlebens (OS) basierend auf der frühen Tumorvolumenreduktion (eTS) in der Phase III Studie von Cabozantinib (Cabo) versus Everolimus (Eve) beim fortgeschrittenen Nierenzellkarzinom (RCC)
29. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
30. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors
31. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy†
32. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
33. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes
34. Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls
35. A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk
36. Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés
37. Lebensqualität-adaptierte Zeit ohne Symptome oder Toxizität (Q-TWiST): Analyse von Cabozantinib (C) gegenüber Sunitinib (S) bei Patienten mit fortgeschrittenem Nierenzellkarzinom (aRCC) und intermediärem/hohem Risiko (Allianz A031203)
38. Erratum: The Immune Landscape of Cancer (Immunity (2018) 48(4) (812–830.e14), (S1074761318301213), (10.1016/j.immuni.2018.03.023))
39. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma
40. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
41. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer
42. Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444.
43. 9 - Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101
44. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
45. METEOR Studie: Retrospektive Analyse von Patienten mit fortgeschrittenem Nierenzellkarzinom bezüglich der Wirksamkeit von Cabozantinib (CABO) vs Everolimus (EVE) in Abhängigkeit vom Nephrektomiestatus
46. Three-Year Efficacy and Safety Update From the Phase III Checkmate 025 Study of Nivolumab (NIVO) v Everolimus (EVE) in Patients With Advanced Renal Cell Carcinoma (aRCC)
47. Comparing long-term outcomes following radical and partial nephrectomy for cT1 renal cell carcinoma in young and healthy individuals
48. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer
49. Variation in positive surgical margin status following radical prostatectomy for pT2 prostate cancer
50. 1158 - Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.